Fresenius Kabi is a global healthcare company that specialises in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Fresenius’s products and services are used to help care for critically and chronically ill patients.
In 2016 Fresenius Kabi purchased Merck Biosimilars giving them a presence in this growing market segment.
In December 2017 Fresenius Kabi commissioned RMG to recruit a UK & Ireland Medical Director for their new Biosimilars division.
Following a thorough and exhaustive process managed by RMG (taking in over 150 individuals from across the immunology market) Fresenius Kabi were able to recruit a GMC registered medical doctor (cardiothoracic surgeon) with extensive experience in medical affairs working as an Associate Medical Director within an organisation focused on Rare Disease and more latterly Multiple Sclerosis. This individual had extensive continental experience and as such his knowledge of compliance legislation both domestically and continentally was intimate. The candidate was able to draw on an extensive network of KOL’s and as such were deemed an asset to Fresenius’s efforts within this area.
RMG’s recruitment process from project signoff to candidate introduction was 8 weeks (including the Christmas break). From this point, Fresenius were able to table an offer and secure the candidate's services within a further 9 weeks.
The candidate will commence employment with Fresenius Kabi in July 2018